Why did Cardiol Therapeutics' operating expenses surge in Q4 2024?

Cardiol Therapeutics' operating expenses surged in Q4 2024 primarily due to the ramp-up costs associated with new products and the increasing internationalization of the business.

The company's expansion into new product lines and its growing international presence contribute to the increase in operating expenses. As Cardiol Therapeutics continues to develop and market new products and expands into new geographic markets, it requires additional resources to support these initiatives. This includes investments in research and development, manufacturing, marketing, and distribution networks. These expenses are necessary for the company's growth and strategic expansion but can lead to short-term increases in operating costs.